Melanoma Stage IV

Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 2 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Evaxion
EvaxionDenmark - Hørsholm
2 programs
1
1
EVX-01Phase 2
EVX-02APhase 1/21 trial
Active Trials
NCT04455503TerminatedEst. Mar 2023
Pierre Fabre
Pierre FabreFrance - Aignan
1 program
EncorafenibN/ASmall Molecule1 trial
Active Trials
NCT04045691Recruiting750Est. Sep 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
EvaxionEVX-02A
Pierre FabreEncorafenib

Clinical Trials (2)

Total enrollment: 750 patients across 2 trials

Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1

Start: Jul 2020Est. completion: Mar 2023
Phase 1/2Terminated

Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment

Start: Oct 2019Est. completion: Sep 2027750 patients
N/ARecruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 750 patients
2 companies competing in this space